Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives Consensus Rating of “Hold” from Analysts

Shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX) have been assigned a consensus recommendation of “Hold” from the ten brokerages that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $38.40.

Several equities research analysts have issued reports on the company. Weiss Ratings began coverage on Seaport Therapeutics in a report on Tuesday. They set a “sell (d+)” rating for the company. Zacks Research upgraded shares of Seaport Therapeutics to a “hold” rating in a report on Wednesday, May 27th. Wall Street Zen raised shares of Seaport Therapeutics to a “hold” rating in a research report on Saturday, May 9th. BNP Paribas Exane cut shares of Seaport Therapeutics to a “market perform” rating in a research note on Tuesday, May 26th. Finally, UBS Group cut shares of Seaport Therapeutics to a “sell” rating in a research note on Tuesday, June 9th.

Seaport Therapeutics Stock Up 2.2%

NASDAQ:SPTX opened at $24.22 on Friday. Seaport Therapeutics has a 12-month low of $14.85 and a 12-month high of $24.65. The company has a market capitalization of $1.30 billion and a price-to-earnings ratio of -2.00. The company has a 50 day simple moving average of $20.36.

Seaport Therapeutics (NASDAQ:SPTX) last issued its earnings results on Monday, August 3rd. The company reported ($1.78) EPS for the quarter, missing the consensus estimate of ($0.71) by ($1.07). On average, equities research analysts forecast that Seaport Therapeutics will post -4.6 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Robert J. Hombach purchased 13,000 shares of the stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $18.14 per share, with a total value of $235,820.00. Following the acquisition, the director directly owned 13,000 shares in the company, valued at $235,820. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Institutional Investors Weigh In On Seaport Therapeutics

An institutional investor recently bought a new position in Seaport Therapeutics stock. TRV GP VI LLC bought a new position in shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 2,061,222 shares of the company’s stock, valued at approximately $44,769,742,000. Seaport Therapeutics accounts for approximately 19.3% of TRV GP VI LLC’s investment portfolio, making the stock its 2nd largest holding. TRV GP VI LLC owned 3.85% of Seaport Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Seaport Therapeutics Company Profile

Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON.